UBS Group’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

UBS Group’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$131	–	11193
2022 Q4	$131	Hold	13	–	–	﹤0.01%	10365
2022 Q3	$0	Hold	13	–	–	﹤0.01%	11424
2022 Q2	$0	Hold	13	–	–	﹤0.01%	11410
2022 Q1	$0	Hold	13	–	–	﹤0.01%	11291
2021 Q4	$0	Hold	13	–	–	﹤0.01%	11033
2021 Q3	$0	Buy	+13	New	+$127	﹤0.01%	10395

Other funds holding ORIA

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

UBS Group's ORIA Position: Q1 2023 in Review

UBS Group sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q1 2023, closing a stake of 13 shares — an estimated $131 sold.

UBS Group first reported a position in ORIA in Q3 2021 and held it in 6 quarters. The position peaked at $131 in Q4 2022. 49 funds tracked by Wall St. Rank hold ORIA as of Q1 2023.

UBS Group reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q1 2023 after selling out during the quarter.
UBS Group sold 13 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q1 2023, an estimated $131.
UBS Group first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 6 quarters.
UBS Group's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $131 in Q4 2022.
49 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.